Quantcast

Latest Bisphosphonate Stories

2011-12-07 21:36:01

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial. Richard de Boer, M.D., of the Royal Melbourne Hospital in Victoria, Australia, presented long-term data from the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) trial at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held...

2011-12-07 11:26:43

Research: Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study People who take bisphosphonates after joint replacement surgery are less likely to need a repeat operation, finds a new study published on bmj.com today. While hip and knee replacements are cost effective procedures, substantial numbers of patients require revision surgery within 10 years to replace the implant because of...

2011-11-18 08:00:00

The US Drug Watchdog is urging women, who suffered a broken femur, or thighbone fracture, for no apparent reason, while they were using the osteoporosis drug called Fosamax to call them, and get identified. According to the FDA, "Typically these fractures occurred after using any type of osteoporosis drug, or Fosamax for five years, or more." The US Drug Watchdog says, "In the instance of Fosamax, we are talking about women, whose leg simply broke. They did not fall, they did not run into...

2011-10-13 05:31:23

(Ivanhoe Newswire) — An osteoporosis drug protects against the bone damaging effects of certain breast cancer medications. According to this study, some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health. Drugs called aromatase inhibitors stop the production of estrogen in postmenopausal women and therefore make less estrogen available to stimulate the growth of certain breast cancer cells. Many postmenopausal women...

2011-10-10 09:17:18

A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health. Drugs called aromatase inhibitors stop the production of estrogen in postmenopausal women and therefore make less...

2011-09-30 05:40:19

(Ivanhoe Newswire) -- A new study suggests adding zoledronic acid to a drug regimen for patients with early stage breast cancer does not improve outcome. Zoledronic acid is a bisphosphonate that is used to treat osteoporosis and prevent skeletal fractures in patients with some types of cancer. In previous studies, bisphosphonates were shown to prevent or delay cancer metastasis and even reduce rates of recurrence and death. Researchers randomly assigned 3,360 patients to receive...

2011-09-26 12:19:48

A trial investigating the use of zoledronic acid to aid chemotherapy for breast cancer has found a significant benefit for post-menopausal women, according to results presented at the 2011 European Multidisciplinary Cancer Congress today (Sunday). Researchers think it could be the key for a greater understanding of the mechanisms of breast cancer recurrence as well as offering new options for patient care. Zoledronic acid is one of the bisphosphonates, a group of drugs mainly used to treat...

2011-09-26 12:17:50

Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomized Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented today (Sunday) at the 2011 European Multidisciplinary Cancer Congress. Professor Peter Hoskin, consultant clinical...

2011-09-05 09:00:00

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, notes a recent possible setback for Canadians who have suffered harm after taking Fosamax. New York, NY (PRWEB) September 05, 2011 In early June 2011, the Quebec Superior Court dismissed a motion seeking authorization of a class action against Merck Canada Inc and Merck & Co Inc on behalf of all natural persons in Quebec who had purchased or taken Fosamax. The petitioner in...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.